Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077931 | 0.73 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL5077933 | 0.73 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL5077934 | 0.73 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL1073890 | 0.71 | ALDH1A1 (0.44) | MAPK1 | |
| SCHEMBL8348766 | 0.71 | ALDH1A1 (0.44) | MAPK1 | |
| SCHEMBL11122429 | 0.71 | ALDH1A1 (0.44) | MAPK1 | |
| SCHEMBL7014418 | 0.71 | ALDH1A1 (0.44) | MAPK1 | |
| SCHEMBL3360230 | 0.70 | TRPA1 (0.37) | — | |
| SCHEMBL15903794 | 0.69 | SHBG (0.36) | MAPK1 | |
| SCHEMBL427801 | 0.69 | ALDH1A1 (0.50) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608713-B2 | Such as 3-(9-phosphabicyclo[3.3.1]nonan-9-yl)-cyclohexan-1-one by reacting phosphine with cyclic alpha,beta-unsaturated carbonyl compound; for use as ligands for metal catalysts or starting materials for preparing phosphonium salts | CYTEC CANADA INC. (CA) | 2009-10-27 | — | — | US | disclosed |
| US-20070037981-A1 | Such as 3-(9-phosphabicyclo[3.3.1]nonan-9-yl)-cyclohexan-1-one by reacting phosphine with cyclic alpha,beta-unsaturated carbonyl compound; for use as ligands for metal catalysts or starting materials for preparing phosphonium salts | CYTEC CANADA INC. (CA) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037981-A1 | Such as 3-(9-phosphabicyclo[3.3.1]nonan-9-yl)-cyclohexan-1-one by reacting phosphine with cyclic alpha,beta-unsaturated carbonyl compound; for use as ligands for metal catalysts or starting materials for preparing phosphonium salts | PHOSPHO1, PLCD1, PLCB3 | MAPK1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.